Meta‐analysis and machine learning reveal the antiobesity effects of melatonin on obese rodents

Summary Melatonin appears to be a promising supplement for obesity treatment. The antiobesity effects of melatonin on obese rodents are influenced by various factors, including the species, sex, the dosage of melatonin, treatment duration, administration via, daily treatment time, and initial body weight (IBW). Therefore, we conducted a meta‐analysis and machine learning study to evaluate the antiobesity effect of melatonin on obese mice or rats from 31 publications. The results showed that melatonin significantly reduced body weight, serum glucose (GLU), triglycerides (TGs), low‐density lipoprotein (LDL), and cholesterol (TC) levels in obese mice or rats but increased high‐density lipoprotein (HDL) levels. Melatonin showed a slight positive effect on clock‐related genes, although the number of studies was limited. Meta‐regression analysis and machine learning indicated that the dosage of melatonin was the primary factor influencing body weight, with higher melatonin dosages leading to a stronger weight reduction effect. Together, male obese C57BL/6 mice and Sprague–Dawley rats with an IBW of 100–200 g showed better body weight reduction when supplemented with a dose of 10–30 mg/kg melatonin administered at night via injection for 5–8 weeks.